GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Fulgent Genetics Inc.
Fulgent Genetics is a genetic testing company. Its stock price soared during the pandemic on demand for PCR tests. The current chart reflects a sharp decline in revenue and the company's search for new growth drivers in oncology and reproductive medicine.
Share prices of companies in the market segment - Medanalysis
Fulgent Genetics provides comprehensive genetic testing services for diagnosis and screening of various diseases. We've categorized it as a "Medical Analysis" company. The chart below shows how investors view the rapidly growing genetic technology and personalized medicine sector.
Broad Market Index - GURU.Markets
Fulgent Genetics provides comprehensive genetic testing services for the diagnosis and screening of various diseases. Its innovativeness earns it a spot in the GURU.Markets index. The chart below compares its performance, reflecting investor expectations, with the overall market picture.
Change in the price of a company, segment, and market as a whole per day
FLGT - Daily change in the company's share price Fulgent Genetics Inc.
Fulgent Genetics shares exhibit extreme volatility associated with the diagnostics sector. change_co measures sensitivity to demand for genetic testing. This metric is the basis for analyzing fast-moving healthcare companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Medanalysis
Fulgent Genetics, Inc. is a genetic testing company. This chart highlights the sector's high volatility. Comparing it to FLGT, whose business has transformed since the pandemic, helps assess its new risk profile.
Daily change in the price of a broad market stock, index - GURU.Markets
Fulgent is a diversified genetics company providing diagnostic and research tests. The oncology diagnostics and genetics sector is extremely sensitive to clinical data and competition. The chart below illustrates the volatility in this niche, reflecting both high expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Fulgent Genetics Inc.
Fulgent, a star of the COVID-testing era, has been actively transforming its business over the past year, focusing on genetic testing and oncology. Its year-over-year share price performance, shown in the chart, reflects the market's assessment of this complex turnaround strategy.
Annual dynamics of market capitalization of the market segment - Medanalysis
Fulgent Genetics, Inc. is a technology company offering a wide range of genetic tests. Following explosive growth in COVID-19 testing, it is now tasked with proving the sustainability of its core business. The chart below shows how the market views its diversified portfolio and the competition in the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Having experienced an incredible boom and subsequent bust in COVID-19 testing, Fulgent is searching for a new identity. Its stock price reflects not economic cycles, but its ability to find new sources of growth in genetic testing. This chart tells the story of how the company is adapting to life after its unprecedented rise.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Fulgent Genetics Inc.
Nexa, a Brazilian mining company, is one of the world's largest zinc producers. The monthly fluctuations on the chart directly reflect global prices for zinc, which is used primarily for galvanizing steel. Global economic activity determines demand for its products.
Monthly dynamics of market capitalization of the market segment - Medanalysis
Fulgent Genetics is at the forefront of genetic testing and diagnostics. The medical diagnostics sector is booming thanks to personalized medicine. Industry dynamics reflect both technological advancements and changes in regulation and reimbursement. Fulgent's success depends on its ability to offer accurate and affordable tests in this context.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Fulgent Genetics, Inc. is a technology company providing a wide range of genetic tests and services. Its business depends on innovations in genomics and demand for diagnostics. The broader market graph allows us to assess how its shift from COVID-19 testing to a broader portfolio of oncology and reproductive testing has impacted its performance, often independent of the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Fulgent Genetics Inc.
Fulgent Genetics provides genetic testing services. The company's weekly stock price is volatile and depends on testing volumes, competition, and changes in insurance reimbursement rates.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Fulgent Genetics is a genetic testing company. Comparing its weekly performance with the healthcare sector reveals its volatility. The chart shows how competition and changes in insurance rates influence its stock price movements differently from those of other diagnostic companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Fulgent, a diagnostics company, lives in a world of its own. Its performance is determined by the decisions of insurance companies. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can move regardless of the broader market.
Market capitalization of the company, segment and market as a whole
FLGT - Market capitalization of the company Fulgent Genetics Inc.
Fulgent Genetics' market capitalization is a dramatic story of rise and fall, driven by the COVID-19 pandemic. The company's stock price skyrocketed thanks to PCR testing. The subsequent decline reflects the question investors are asking: can the company use its profits to build a sustainable business in other areas of genetic testing?
FLGT - Share of the company's market capitalization Fulgent Genetics Inc. within the market segment - Medanalysis
Fulgent Genetics provides comprehensive genetic testing services, including diagnostics for hereditary diseases and oncology. The company's market share in the medical analytics sector reflects its rapid growth and technological platform. The chart below shows Fulgent's market share in a market where genetics is transforming medicine.
Market capitalization of the market segment - Medanalysis
Fulgent Genetics provides comprehensive genetic testing services, including COVID-19 tests and oncology panels. The chart below shows the overall market capitalization of the medical testing sector. Its dynamics reflect both the pandemic boom and the long-term growth in demand for genetic diagnostics.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Fulgent Genetics line on this chart is the story of the rise and fall of a "COVID" hero. The company became known for its PCR tests. Its market cap soared during the pandemic, and now the chart shows the difficult search for a new growth point in the post-COVID world of genetic testing.
Book value capitalization of the company, segment and market as a whole
FLGT - Book value capitalization of the company Fulgent Genetics Inc.
Fulgent Genetics' foundation is its high-tech laboratories and platform for conducting a wide range of genetic tests, from hereditary disease diagnostics to oncology. This represents scientific and technological capital. The chart will show how the company, particularly after the surge in COVID-19 testing, managed its capital and expanded its core business.
FLGT - Share of the company's book capitalization Fulgent Genetics Inc. within the market segment - Medanalysis
Fulgent Genetics offers a wide range of genetic tests. The company's strength lies in its automated and high-throughput laboratories. The chart shows the proportion of the physical laboratory infrastructure required to conduct complex genetic analyses that Fulgent controls.
Market segment balance sheet capitalization - Medanalysis
Genetic testing like Fulgent's requires high-tech laboratories. Compared to its healthcare assets, this makes the company moderately capital-intensive. Its diagnostic services rely on complex and expensive physical infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Fulgent Genetics' assets are highly automated laboratories offering a wide range of genetic tests, from hereditary disease diagnostics to oncology. Its book value reflects its technology platform, which enables testing quickly and affordably. The chart illustrates the company's scale in the genetics field.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Fulgent Genetics Inc.
Fulgent Genetics, a genetic testing company, is valued at a premium to its laboratories. Investors value its technology platform, broad range of tests, and its potential for growth in both oncology and reproductive medicine.
Market to book capitalization ratio in a market segment - Medanalysis
Fulgent Genetics offers a wide range of genetic tests. The company has grown significantly during the pandemic thanks to PCR testing. The chart shows how investors assess its ability to maintain growth in the post-pandemic era through its core businesses in oncology and reproductive medicine.
Market to book capitalization ratio for the market as a whole
Fulgent Genetics offers a wide range of genetic tests, from hereditary disease diagnostics to oncology. The company has seen explosive growth during the pandemic thanks to its COVID tests. This metric reflects how investors assess its ability to maintain growth momentum post-pandemic and gain a foothold in the core genetic diagnostics market.
Debts of the company, segment and market as a whole
FLGT - Company debts Fulgent Genetics Inc.
Fulgent Genetics, a genetic testing company, experienced explosive growth during the pandemic thanks to COVID-19 testing. It is now using its accumulated capital to invest in its core business and make acquisitions, while maintaining low debt. This chart reflects its transition from pandemic success to sustained growth in the post-COVID era.
Market segment debts - Medanalysis
Fulgent Genetics provides a wide range of genetic tests, including diagnostics for hereditary diseases and oncology. The company experienced significant growth during the pandemic thanks to COVID-19 testing. This chart shows how Fulgent has managed its capital since this surge, reinvesting in its core diagnostics business and through acquisitions.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Fulgent Genetics Inc.
Fulgent Genetics offers a wide range of genetic tests, including diagnostics for hereditary diseases and cancer testing. Competition in this field requires ongoing investment in new sequencing technologies and bioinformatics. This chart shows how the company uses debt to finance its technological development and laboratory expansion.
Market segment debt to market segment book capitalization - Medanalysis
Fulgent Genetics provides a wide range of genetic tests, including diagnostics for hereditary diseases and oncology. Demand for its services has surged during the pandemic. This chart shows how the company is managing its debt after a period of rapid growth, comparing it to the market capitalization of the entire medical diagnostics sector.
Debt to book value of all companies in the market
Fulgent Genetics offers a wide range of genetic tests. The medical diagnostics industry is rapidly evolving and requires significant investment in technology and research. How dependent is Fulgent on debt to maintain its innovative leadership? This chart of total market debt provides context for assessing its financial policies.
P/E of the company, segment and market as a whole
P/E - Fulgent Genetics Inc.
Fulgent Genetics is a technology company providing genetic testing services. This chart shows how investors valued the company during the pandemic, when it became a major provider of COVID-19 tests, and afterwards. This valuation reflects its transition back to its core business of genetic sequencing.
P/E of the market segment - Medanalysis
Fulgent Genetics is a technology company providing comprehensive genetic testing services, including next-generation sequencing, for physicians and patients. This chart shows the average rating for the healthcare analytics sector, helping to understand how the market views Fulgent's technology platform and diagnostic capabilities.
P/E of the market as a whole
Fulgent Genetics offers a wide range of genetic tests. The company has seen significant growth in COVID-19 testing. Does its current valuation reflect a normalization of demand after the pandemic, or do investors believe it can use its new capital to grow in other, more resilient segments of genetic diagnostics?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Fulgent Genetics Inc.
Fulgent Genetics is a technology company offering a wide range of genetic tests, including diagnostics for hereditary diseases and cancer testing. This chart shows future revenue expectations, which depend on the growth of the genetic testing market and the company's ability to offer competitive and accurate assays.
%20P%2FE%20Fulgent%20Genetics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Fulgent-Genetics-Inc.&v=1772613597981 "Chart of the company's future (projected) P/E Fulgent Genetics Inc.")
Future (projected) P/E of the market segment - Medanalysis
Fulgent Genetics provides comprehensive genetic testing services, including diagnostics for hereditary diseases, cancer testing, and COVID-19 testing. The chart shows forecasts for the medical diagnostics sector. This allows one to assess how the market perceives Fulgent's ability to compete on price and quality in the rapidly growing but fragmented genetic testing industry.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772613597982 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Fulgent Genetics, Inc. provides genetic testing services. The company gained widespread recognition for its COVID-19 tests and is now focusing on oncology and rare diseases. This market sentiment chart helps gauge how investors view the company's transition to a more sustainable business model.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772613597999 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Fulgent Genetics Inc.
Fulgent Genetics offers a wide range of genetic tests, including diagnostics for hereditary diseases and oncology. The company's profits depend on testing volume and the efficiency of its laboratory processes. This chart shows how the company is growing alongside the genetic diagnostics and personalized medicine market.
Profit of companies in the market segment - Medanalysis
Fulgent Genetics provides comprehensive genetic testing services, including diagnostics for hereditary diseases and cancer testing. This chart, which reflects the profitability of the medical testing sector, demonstrates how genetics is changing medicine. Their technology platform enables rapid and cost-effective testing, making them a key player in this rapidly growing market.
Overall market profit
Fulgent Genetics offers a wide range of genetic tests, including diagnostics for hereditary diseases and cancer testing. The company's growth is driven by advances in personalized medicine. Overall economic stability, reflected in this graph, is important for the healthcare system to afford the implementation of advanced and expensive testing technologies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Fulgent Genetics Inc.
Fulgent Genetics offers a wide range of genetic tests, including diagnostics for hereditary diseases, oncology tests, and COVID-19 testing. The company's future is tied to the growth of personalized medicine. This chart reflects analyst forecasts for testing volume, excluding peak revenues due to COVID-19, and growth in key segments.
%20profit%20of%20the%20company%20Fulgent%20Genetics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Fulgent-Genetics-Inc.&v=1772613598024 "Graph of future (projected) profit of the company Fulgent Genetics Inc.")
Future (predicted) profit of companies in the market segment - Medanalysis
Fulgent Genetics provides comprehensive genetic testing services, including diagnostics for hereditary diseases and oncology. The company's growth depends on the expanding application of genetics in medicine. This chart for the medical diagnostics sector reflects the overall expectations for the growth of personalized medicine and the demand for innovative diagnostic tests.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772613598060 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
Fulgent Genetics offers a wide range of genetic tests. Demand for its services depends on both technological advances and the state of the healthcare system. This graph, reflecting general economic expectations, indirectly impacts healthcare budgets and people's willingness to spend on preventive care.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772613598077 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Fulgent Genetics Inc.
Fulgent Genetics is a technology company providing comprehensive genetic testing services. The chart shows a high valuation for each dollar of its revenue. This reflects investor confidence in the growth of the genetic diagnostics market, particularly in oncology and reproductive health, and the company's ability to offer rapid and affordable testing.
P/S market segment - Medanalysis
Fulgent Genetics provides comprehensive genetic testing services for disease diagnosis and screening. The company's revenue depends on testing volumes, which can fluctuate significantly due to external factors, as demonstrated by the pandemic. This chart reflects the average valuation in the sector, helping to assess the market's perception of Fulgent's long-term business prospects.
P/S of the market as a whole
Fulgent Genetics is a technology company providing comprehensive genetic testing services, including diagnostics for hereditary diseases, oncology, and COVID-19 testing. This chart, showing the average market revenue estimate, helps understand the premium investors are willing to pay for cutting-edge genetic technologies and their growing medical applications.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Fulgent Genetics Inc.
Fulgent Genetics offers a wide range of genetic tests, including diagnostics for hereditary diseases and cancer testing. Following the pandemic, the company is focusing on its core business. This chart reflects investor expectations for future revenue growth from basic genetic testing, not related to COVID-19.
%20P%2FS%20Fulgent%20Genetics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Fulgent-Genetics-Inc.&v=1772613598121 "The graph of the company's future (projected) P/S Fulgent Genetics Inc.")
Future (projected) P/S of the market segment - Medanalysis
Fulgent Genetics is a technology company providing comprehensive genetic testing services, including diagnostics for hereditary diseases and cancer testing. The company actively uses technology to reduce costs. This chart shows the average estimated future sales in the medical diagnostics sector. It helps understand how the market views Fulgent's competitive position.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772613598146 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
Fulgent Genetics offers a wide range of genetic tests, including diagnostics for hereditary diseases and cancer testing. This chart reflects overall investor sentiment. The company's growth is driven by the trend toward personalized medicine. Fulgent's ability to quickly adapt and introduce new tests, as it did during the pandemic, is key to its success.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772613598231 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Fulgent Genetics Inc.
This chart shows the revenue of Fulgent Genetics, a technology company specializing in genetic testing. It offers a wide range of tests for diagnosing hereditary diseases and cancer. Sales dynamics reflect the growth of the genetic testing market and the company's ability to compete on both price and service quality.
Sales of companies in the market segment - Medanalysis
Fulgent Genetics is a technology company providing comprehensive genetic testing services, including diagnostics for hereditary diseases and cancer testing. This chart illustrates the rapid growth of the genetics market. Fulgent's platform, combining cutting-edge technology and affordable pricing, makes genetic testing more accessible to doctors and patients.
Overall market sales
Fulgent Genetics offers a wide range of genetic tests, including diagnostics for hereditary diseases and oncology. Demand for its services is growing with the advancement of personalized medicine. The overall economic situation, reflected in this chart, impacts healthcare budgets and insurance coverage for such tests.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Fulgent Genetics Inc.
Fulgent Genetics offers a wide range of genetic tests, including diagnostics for hereditary diseases and cancer testing. The company's future revenue depends on the development of personalized medicine. The chart shows analysts' forecasts for genetic testing market growth.
%20sales%20of%20the%20company%20Fulgent%20Genetics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Fulgent-Genetics-Inc.&v=1772613598272 "Schedule of future (projected) sales of the company Fulgent Genetics Inc.")
Future (projected) sales of companies in the market segment - Medanalysis
Fulgent Genetics provides comprehensive genetic testing services, including diagnostics for hereditary diseases, cancer testing, and COVID-19 testing. The company uses technology and automation to reduce costs. This chart shows the forecast for the medical diagnostics market, where genetics plays an increasingly important role.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772613598285 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
Fulgent Genetics offers a wide range of genetic tests, including diagnostics for hereditary diseases and oncology. The company's growth is driven by the development of personalized medicine. This chart shows general economic trends, but for Fulgent, the key drivers are technological innovations in DNA sequencing and expanded insurance coverage for genetic testing.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772613598323 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Fulgent Genetics Inc.
Fulgent Genetics offers a wide range of genetic tests, including diagnostics for hereditary diseases and oncology. Its profitability depends on testing volume and insurance reimbursement. This chart shows how the company monetizes cutting-edge genomics technologies, remaining at the forefront of personalized medicine.
Market segment marginality - Medanalysis
Fulgent Genetics is a technology company offering a wide range of genetic tests, including diagnostics for hereditary diseases and cancer testing. Profitability depends on testing volume, insurance reimbursement, and the efficiency of their laboratory processes. This chart shows their operating results. Comparison with competitors highlights their technological platform.
Market marginality as a whole
Fulgent Genetics is a technology company providing genetic testing services. They offer a wide range of tests, from hereditary disease diagnostics to oncology. This overall profitability curve is not important to them. Their growth is driven by innovations in genetics, the expansion of their testing portfolio and its acceptance in clinical practice, and insurance coverage.
Employees in the company, segment and market as a whole
Number of employees in the company Fulgent Genetics Inc.
Fulgent Genetics offers a wide range of genetic tests. Its team consists of laboratory technicians, geneticists, and bioinformaticians. This chart reflects the scale of its laboratory capacity and its ability to process a large number of tests, the demand for which has grown significantly in recent years.
Share of the company's employees Fulgent Genetics Inc. within the market segment - Medanalysis
Fulgent Genetics provides comprehensive genetic testing services for diagnosis and screening of various diseases. This chart reflects the company's workforce in the high-tech medical sector. This growth reflects the expansion of its laboratory capacity and team of bioinformaticians who analyze complex genetic data.
Number of employees in the market segment - Medanalysis
Fulgent Genetics, Inc. is a technology company providing comprehensive genetic testing services. This chart illustrates employment trends in the genetic diagnostics sector. The surge in hiring in recent years reflects not only the growing demand for traditional tests but also the company's significant role in COVID-19 testing, demonstrating the flexibility of its technology platform.
Number of employees in the market as a whole
Fulgent Genetics is a technology company providing comprehensive genetic testing services. It is best known for its COVID-19 tests, but also offers a wide range of cancer and genetic testing. This chart shows how the growth of genetic diagnostics, driven by companies like Fulgent, is creating high-tech jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Fulgent Genetics Inc. (FLGT)
Fulgent Genetics is a genetic testing company. This chart reflects the high value of its intellectual capital. Fulgent's key assets are its technology platform, library of tests, and ability to rapidly develop new ones (as was the case with COVID-19). The chart shows how highly the market values this flexible and scalable platform per employee.
%20of%20the%20company%20Fulgent%20Genetics%20Inc.%20(FLGT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Fulgent-Genetics-Inc.-FLGT&v=1772613598424 "Chart of market capitalization per employee (in thousands of dollars) of the company Fulgent Genetics Inc. (FLGT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Fulgent Genetics offers a wide range of genetic tests, including diagnostics for hereditary diseases and cancer testing. It is a high-tech laboratory that utilizes automation and bioinformatics. This chart demonstrates the high market recognition of its technology and its ability to process high test volumes.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772613598424 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Fulgent Genetics is a technology company providing genetic testing services. This chart shows how the market values this company, which operates at the intersection of healthcare and technology. The high cost per employee reflects the level of automation in its laboratories and the value of its genetic data and analytics platforms.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772613598434 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Fulgent Genetics Inc. (FLGT)
Fulgent Genetics is a genetic testing company. They rose to prominence during the pandemic, becoming one of the largest suppliers of COVID-19 tests. This graph would show a huge surge: their highly automated labs allowed their small team to process millions of tests, generating massive profits.
%20Chart%20Fulgent%20Genetics%20Inc.%20(FLGT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Fulgent-Genetics-Inc.-FLGT&v=1772613598438 "Company Profit Per Employee (in thousands of dollars) Chart Fulgent Genetics Inc. (FLGT)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Fulgent Genetics (FLGT) is a genetic testing company. They offer a wide range of tests (oncology, reproductive health). During the pandemic, they became a giant in COVID testing. This reflects their ability to manage both high-volume (COVID) and complex niche tests.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772613598445 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Fulgent Genetics is a biotech company providing genetic testing (oncology, reproductive health). They became famous for their COVID tests. This chart shows how profitable their core (non-COVID) business is. It reflects the profitability of their tests in a highly competitive environment and the automation of their labs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772613598446 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Fulgent Genetics Inc. (FLGT)
Fulgent Genetics provides comprehensive genetic testing, including diagnostics for hereditary diseases and cancer testing. This chart demonstrates the commercial success of its technology platform. The growth in revenue per employee reflects the widespread adoption of its tests, the automation of lab processes, and the ability to process large volumes of tests.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Fulgent-Genetics-Inc.-FLGT&v=1772613598470 "Sales chart per company employee Fulgent Genetics Inc. (FLGT)")
Sales per employee in the market segment - Medanalysis
Fulgent Genetics is a technology company offering a wide range of genetic tests, including COVID-19 tests and cancer panels. This chart shows the revenue generated by each employee (lab technician, geneticist, software developer). This allows us to assess their productivity in the medical diagnostics segment.
Sales per employee for the market as a whole
Fulgent Genetics (FLGT) is a genetic testing company. During the pandemic, it became a major player in COVID-19 testing, leading to explosive growth. This chart shows how a company with a high degree of laboratory automation can scale revenue. This figure now reflects a return to its core, more stable business.
Short shares by company, segment and market as a whole
Shares shorted by company Fulgent Genetics Inc. (FLGT)
Fulgent Genetics, Inc. is a genetic testing company that has made huge profits from COVID-19 testing. This chart shows bearish bets that the company's revenue will plummet after the pandemic ends, leaving its core genetic testing business unable to compensate.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Fulgent-Genetics-Inc.-FLGT&v=1772613598499 "Short Shares Chart for the Company Fulgent Genetics Inc. (FLGT)")
Shares shorted by market segment - Medanalysis
Fulgent Genetics is a genetic testing company. During the pandemic, they made a fortune on PCR tests. This chart shows short bets. The "short" here is a bet that their core (non-COVID) genetic testing business is too small and unprofitable to sustain the company.
Shares shorted by the overall market
Fulgent Genetics offers a wide range of genetic tests. The company has grown strongly on COVID-19 testing. With this chart reflecting rising general pessimism, investors are re-evaluating the "heroes of the pandemic." The question for FLGT is: will their core oncology and reproductive businesses be able to offset the decline in COVID-19 revenue?
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Fulgent Genetics Inc. (FLGT)
Fulgent Genetics (FLGT) is a technology company providing genetic testing services. They rose to prominence during the pandemic, becoming a major supplier of COVID-19 tests. This chart measures momentum. It shows "oversold" (below 30) amid a sharp decline in demand for COVID tests, or "overbought" (above 70) amid expectations for growth in their core oncology business.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Fulgent-Genetics-Inc.-FLGT&v=1772613598579 "RSI 14 indicator chart for the company's stock Fulgent Genetics Inc. (FLGT)")
RSI 14 Market Segment - Medanalysis
Fulgent Genetics (FLGT) is a technology company providing genetic testing services (from COVID to cancer). The RSI_14_Seg for "Medanalysis" (diagnostics) shows the "temperature" in this cutting-edge sector. The chart helps us understand: is FLGT's decline a post-COVID decline, or is the entire sector oversold?
RSI 14 for the overall market
Fulgent Genetics (FLGT) develops genomic tests. This chart reflects insurance companies' willingness to pay for expensive innovations. During periods of euphoria and budget growth, they more readily approve new tests. During times of panic and cost savings, insurers may tighten requirements, preferring older, cheaper methods.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast FLGT (Fulgent Genetics Inc.)
Fulgent Genetics offers a wide range of genetic tests, including those for COVID-19, oncology, and rare diseases. This chart shows the average 12-month forecast from analysts. It reflects their complex assessment of the company's post-COVID business and the profitability of its core genetics segment.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-FLGT-Fulgent-Genetics-Inc.&v=1772613598624 "A chart showing analyst consensus forecasts for the expected stock price. FLGT (Fulgent Genetics Inc.)")
The difference between the consensus estimate and the actual stock price FLGT (Fulgent Genetics Inc.)
Fulgent Genetics is a high-tech laboratory. The company skyrocketed with COVID testing and is now returning to its core business—complex genetic testing (for oncology and rare diseases). This chart shows the difference between the consensus forecast and the price. It reflects whether analysts believe the company can grow beyond COVID-19.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-FLGT-Fulgent-Genetics-Inc.&v=1772613598629 "A chart showing the difference between the consensus forecast and the actual stock price. FLGT (Fulgent Genetics Inc.)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Fulgent Genetics is a technology company providing a wide range of genetic tests (from rare childhood diseases to oncology) and sequencing services for laboratories. This chart shows analysts' overall expectations for the medical testing sector. It reflects whether experts believe the genetic diagnostics market will grow.
Analysts' consensus forecast for the overall market share price
Fulgent Genetics is a high-tech diagnostic lab. They skyrocketed with COVID testing and are now focusing on genetics (oncology). This chart, reflecting expert expectations, is a barometer for them. During a recession (pessimism), patients skimp on expensive genetic tests.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Fulgent Genetics Inc.
Fulgent Genetics is a genetic testing technology company. They skyrocketed with COVID-19 testing and are now using those resources to build a more sustainable core business in oncology and reproductive genetics. This chart is an indicator of their transformation. It likely reflects their ability to grow their core business, offsetting the decline in revenue due to the coronavirus.
AKIMA Market Segment Index - Medanalysis
Fulgent (FLGT) is a high-tech diagnostics company; the company (which skyrocketed with COVID tests) owns a genomic testing platform (for rare diseases and cancer). This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this technological (testing) model (FLGT) differentiate it from the average pharma company?
The AKIM Index for the overall market
Fulgent Genetics is a technology company offering a wide range of genetic tests (from oncology to rare diseases). It is known for the flexibility of its platform. This chart, reflecting the market average, is a backdrop. It helps assess how Fulgent Genetics, which is rebuilding after the COVID boom, compares to overall macroeconomic trends in diagnostics.
